{"id":35878,"date":"2025-06-24T17:41:49","date_gmt":"2025-06-24T09:41:49","guid":{"rendered":"https:\/\/flcube.com\/?p=35878"},"modified":"2025-06-24T17:41:50","modified_gmt":"2025-06-24T09:41:50","slug":"formation-bio-licenses-gusacitinib-to-sanofi-for-novel-indication-study","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=35878","title":{"rendered":"Formation Bio Licenses Gusacitinib to Sanofi for Novel Indication Study"},"content":{"rendered":"\n

US-based AI-native pharma company Formation Bio announced the licensing of gusacitinib, an oral dual JAK\/SYK inhibitor, to Sanofi (NASDAQ: SNY<\/a>) from its subsidiary Libertas Bio. The agreement includes an upfront payment and potential milestone payments totaling up to EUR 545 million (USD 642 million), plus tiered royalties on future sales.<\/p>\n\n\n\n

Sanofi’s Development Plans<\/strong>
Sanofi will conduct a Phase I study to explore gusacitinib’s potential in novel, previously unstudied indications. This marks the transition of gusacitinib to next-phase development under Sanofi’s global commercialization expertise.<\/p>\n\n\n\n

Background of Gusacitinib Acquisition<\/strong>
Formation Bio, formerly known as TrialSpark, acquired gusacitinib from Asana BioSciences as part of a broader portfolio deal. This transaction represents a significant step forward in the drug’s development journey.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US-based AI-native pharma company Formation Bio announced the licensing of gusacitinib, an oral dual JAK\/SYK…<\/p>\n","protected":false},"author":1,"featured_media":35885,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[65,4176,4177,867,147,33],"class_list":["post-35878","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-auto-immune","tag-formation-bio","tag-libertas-bio","tag-nasdaq-sny","tag-sanofi","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"\nFormation Bio Licenses Gusacitinib to Sanofi for Novel Indication Study - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based AI-native pharma company Formation Bio announced the licensing of gusacitinib, an oral dual JAK\/SYK inhibitor, to Sanofi (NASDAQ: SNY) from its subsidiary Libertas Bio. The agreement includes an upfront payment and potential milestone payments totaling up to EUR 545 million (USD 642 million), plus tiered royalties on future sales.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=35878\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Formation Bio Licenses Gusacitinib to Sanofi for Novel Indication Study\" \/>\n<meta property=\"og:description\" content=\"US-based AI-native pharma company Formation Bio announced the licensing of gusacitinib, an oral dual JAK\/SYK inhibitor, to Sanofi (NASDAQ: SNY) from its subsidiary Libertas Bio. The agreement includes an upfront payment and potential milestone payments totaling up to EUR 545 million (USD 642 million), plus tiered royalties on future sales.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=35878\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-24T09:41:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-24T09:41:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2404.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35878#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35878\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Formation Bio Licenses Gusacitinib to Sanofi for Novel Indication Study\",\"datePublished\":\"2025-06-24T09:41:49+00:00\",\"dateModified\":\"2025-06-24T09:41:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35878\"},\"wordCount\":134,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35878#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2404.webp\",\"keywords\":[\"Auto-immune\",\"Formation Bio\",\"Libertas Bio\",\"NASDAQ: SNY\",\"Sanofi\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35878#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35878\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=35878\",\"name\":\"Formation Bio Licenses Gusacitinib to Sanofi for Novel Indication Study - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35878#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35878#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2404.webp\",\"datePublished\":\"2025-06-24T09:41:49+00:00\",\"dateModified\":\"2025-06-24T09:41:50+00:00\",\"description\":\"US-based AI-native pharma company Formation Bio announced the licensing of gusacitinib, an oral dual JAK\\\/SYK inhibitor, to Sanofi (NASDAQ: SNY) from its subsidiary Libertas Bio. The agreement includes an upfront payment and potential milestone payments totaling up to EUR 545 million (USD 642 million), plus tiered royalties on future sales.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35878#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35878\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35878#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2404.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2404.webp\",\"width\":1080,\"height\":608,\"caption\":\"Formation Bio Licenses Gusacitinib to Sanofi for Novel Indication Study\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35878#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Formation Bio Licenses Gusacitinib to Sanofi for Novel Indication Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Formation Bio Licenses Gusacitinib to Sanofi for Novel Indication Study - Insight, China's Pharmaceutical Industry","description":"US-based AI-native pharma company Formation Bio announced the licensing of gusacitinib, an oral dual JAK\/SYK inhibitor, to Sanofi (NASDAQ: SNY) from its subsidiary Libertas Bio. The agreement includes an upfront payment and potential milestone payments totaling up to EUR 545 million (USD 642 million), plus tiered royalties on future sales.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=35878","og_locale":"en_US","og_type":"article","og_title":"Formation Bio Licenses Gusacitinib to Sanofi for Novel Indication Study","og_description":"US-based AI-native pharma company Formation Bio announced the licensing of gusacitinib, an oral dual JAK\/SYK inhibitor, to Sanofi (NASDAQ: SNY) from its subsidiary Libertas Bio. The agreement includes an upfront payment and potential milestone payments totaling up to EUR 545 million (USD 642 million), plus tiered royalties on future sales.","og_url":"https:\/\/flcube.com\/?p=35878","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-24T09:41:49+00:00","article_modified_time":"2025-06-24T09:41:50+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2404.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=35878#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=35878"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Formation Bio Licenses Gusacitinib to Sanofi for Novel Indication Study","datePublished":"2025-06-24T09:41:49+00:00","dateModified":"2025-06-24T09:41:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=35878"},"wordCount":134,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=35878#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2404.webp","keywords":["Auto-immune","Formation Bio","Libertas Bio","NASDAQ: SNY","Sanofi","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=35878#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=35878","url":"https:\/\/flcube.com\/?p=35878","name":"Formation Bio Licenses Gusacitinib to Sanofi for Novel Indication Study - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=35878#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=35878#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2404.webp","datePublished":"2025-06-24T09:41:49+00:00","dateModified":"2025-06-24T09:41:50+00:00","description":"US-based AI-native pharma company Formation Bio announced the licensing of gusacitinib, an oral dual JAK\/SYK inhibitor, to Sanofi (NASDAQ: SNY) from its subsidiary Libertas Bio. The agreement includes an upfront payment and potential milestone payments totaling up to EUR 545 million (USD 642 million), plus tiered royalties on future sales.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=35878#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=35878"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=35878#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2404.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2404.webp","width":1080,"height":608,"caption":"Formation Bio Licenses Gusacitinib to Sanofi for Novel Indication Study"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=35878#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Formation Bio Licenses Gusacitinib to Sanofi for Novel Indication Study"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2404.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35878"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35878\/revisions"}],"predecessor-version":[{"id":35886,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35878\/revisions\/35886"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/35885"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}